Overview

A Study to Investigate Safety and Tolerability of NDX-3315 in Healthy Participants and Patients With Eosinophilic Esophagitis

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
An open-label phase 1b study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 in healthy participants and patients with eosinophilic esophagitis (EoE).
Phase:
Phase 1
Details
Lead Sponsor:
NexEos Diagnostics, Inc.